Bellerophon Therapeutics Inc (BLPH)

[powerbattles]

Bellerophon Therapeutics announces FDA clearance of initiation of Phase 3 study of INOpulse iNO therapy as treatment for COVID-19
8:37 AM ET 5/11/20 | Briefing.com
Related Quotes


2:14 PM ET 5/11/20
Symbol Last % Chg
BLPH
20.30 19.34%
Real time quote.

Bellerophon Therapeutics today announced that the FDA accepted its Investigational New Drug (IND) application, allowing the company to initiate a Phase 3 study of INOpulse inhaled nitric oxide (iNO) therapy in up to 500 patients infected with COVID-19.The IND acceptance follows agreement by the FDA earlier this year to allow investigational treatment with INOpulse for COVID-19 patients under emergency expanded access. To date, over 50 patients with COVID-19 have received treatment with INOpulse under the care and supervision of their physicians.